Amphastar Pharmaceuticals (AMPH) Projected to Announce Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) is projected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Amphastar Pharmaceuticals to announce earnings of $0.8640 per share and revenue of $197.52 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, analysts expect Amphastar Pharmaceuticals to post $2.43 EPS for the current fiscal year and $2.55 EPS for the next fiscal year.

Amphastar Pharmaceuticals Trading Up 3.0%

Shares of AMPH opened at $26.33 on Thursday. The stock has a market capitalization of $1.12 billion, a P/E ratio of 15.58, a PEG ratio of 4.84 and a beta of 0.90. Amphastar Pharmaceuticals has a twelve month low of $16.65 and a twelve month high of $29.52. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The firm has a fifty day simple moving average of $24.54 and a two-hundred day simple moving average of $22.32.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $23.94, for a total transaction of $239,400.00. Following the transaction, the executive vice president owned 169,203 shares in the company, valued at approximately $4,050,719.82. This represents a 5.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Richard K. Prins sold 7,973 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total transaction of $161,851.90. Following the transaction, the director owned 29,625 shares in the company, valued at approximately $601,387.50. This trade represents a 21.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 33,479 shares of company stock worth $763,922. Corporate insiders own 29.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on AMPH. Wall Street Zen downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 24th. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Weiss Ratings upgraded Amphastar Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 16th. Barclays increased their target price on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 18th. Finally, Wells Fargo & Company increased their target price on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $22.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a biopharmaceutical company that develops, manufactures and markets injectable, inhalation and intranasal products. The company focuses on technically challenging medicines, including complex generics, proprietary products and products based on its drug-delivery technologies.

Its product portfolio includes Primatene MIST, an over-the-counter epinephrine inhaler; Baqsimi, a nasal glucagon product used to treat severe hypoglycemia; and injectable medicines such as glucagon, naloxone, enoxaparin and hyaluronidase.